SAREPTA THERAPEUTICS, INC. Business Combination, Contingent Consideration, Liability, Noncurrent
SAREPTA THERAPEUTICS, INC. (SRPT) had Business Combination, Contingent Consideration, Liability, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent · last filed 2026-03-02
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Noncurrent $0.00.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Noncurrent $300.00K.
- 2024-12-31: Business Combination, Contingent Consideration, Liability, Noncurrent $47.40M.
| Period end | Business Combination, Contingent Consideration, Liability, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-06 |
| 2024-12-31 | $47.40M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |